Comparative Pharmacology
Head-to-head clinical analysis: LAMIVUDINE ZIDOVUDINE 150 MG 300 MG TABLETS CO PACKAGED WITH NEVIRAPINE 200 MG TABLETS versus LAMIVUDINE ZIDOVUDINE NEVIRAPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMIVUDINE ZIDOVUDINE 150 MG 300 MG TABLETS CO PACKAGED WITH NEVIRAPINE 200 MG TABLETS versus LAMIVUDINE ZIDOVUDINE NEVIRAPINE.
Lamivudine/Zidovudine 150 mg/300 mg Tablets Co-packaged with Nevirapine 200 mg Tablets vs LAMIVUDINE; ZIDOVUDINE; NEVIRAPINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lamivudine and zidovudine are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV-1 reverse transcriptase by competitive inhibition and chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase and blocks RNA-dependent and DNA-dependent DNA polymerase activities.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 and HBV reverse transcriptase. Zidovudine is also an NRTI that inhibits HIV-1 reverse transcriptase. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that directly binds to HIV-1 reverse transcriptase and inhibits RNA-dependent and DNA-dependent DNA polymerase activities. The combination inhibits HIV replication.
One tablet (lamivudine 150 mg/zidovudine 300 mg) orally twice daily, plus one tablet (nevirapine 200 mg) orally once daily for first 14 days, then one tablet (nevirapine 200 mg) orally twice daily thereafter.
One tablet (150 mg lamivudine, 300 mg zidovudine, 200 mg nevirapine) orally twice daily.
None Documented
None Documented
Lamivudine: terminal half-life 5-7 hours in adults; prolonged in renal impairment. Zidovudine: terminal half-life 1.1-1.3 hours; prolonged to 1.7 hours in renal impairment. Nevirapine: terminal half-life 45 hours (single dose), reducing to 25-30 hours after multiple dosing due to autoinduction.
Lamivudine: 5-7 hours in adults, prolonged in renal impairment; Zidovudine: 0.5-3 hours, prolonged in hepatic impairment; Nevirapine: 25-30 hours (single dose), 40-45 hours after multiple doses due to autoinduction.
Lamivudine: primarily renal excretion of unchanged drug (approximately 70% within 24 hours) via glomerular filtration and active tubular secretion. Zidovudine: renal excretion (approximately 14% unchanged) and hepatic metabolism to GAZT (glucuronide), with 74% of dose recovered in urine as total zidovudine and metabolites. Nevirapine: 81% of dose recovered in urine (primarily metabolites) and 10% in feces; <5% excreted unchanged in urine.
Lamivudine: ~70% unchanged in urine via glomerular filtration and active tubular secretion; Zidovudine: ~75% metabolized to inactive glucuronide (G-ZDV), ~20% excreted unchanged in urine; Nevirapine: ~80% metabolized by CYP3A4/2B6, ~10% unchanged in urine, ~1% in feces.
Category A/B
Category A/B
NRTI
NRTI